Back to Agenda
Session 5C (Clinical Development Track): Oncology
Session Chair(s)
Steve Hughes, MD
Vice President, Clinical Development
Isis Pharmaceuticals, Inc., United States
Yang-min (Max) Ning
Medical Officer, Division of Oncology Products, OND/OHOP/CDER
FDA, United States
Clinical programs utilizing oligonucleotide therapeutics have been around since the days of polyIC induction of interferon as a mechanism of oncolytic activity. These programs were followed by attempts using first generation phosphorothioate oligodeoxynucleotides to target single genes known to be critical for tumor survival or replication. This session will focus on more recent efforts to use newer generation antisense (Gen2.5) and siRNA to target key genes and a novel approach of administering a microRNA mimetic that represses key evolutionarily conserved pathways to alter tumor growth.
Speaker(s)
Development of MRX34, the First microRNA Mimic in the Clinic
Sinil Kim, MD
Mirna Therapeutics, United States
Chief Medical Officer
Development of Next Generation Anti-sense Molecules for Therapeutic Utility in Oncology
David Blakey, PhD
AstraZeneca, United Kingdom
Chief Scientist, Oncology
Tekmira
Ian MacLachlan, PhD
Tekmira Pharmaceuticals Corporation, Canada
Executive Vice President and Chief Scientific Officer
Have an account?